Blue Owl Orchestrates Major $4 Billion Debt Package for PCI Pharma

In a significant development in the financial landscape, Blue Owl Capital has taken the lead in structuring an impressive $4 billion debt deal aimed at facilitating the growth trajectory of PCI Pharma Services. This move is poised to enhance PCI Pharma’s operational capabilities and expand its service offerings in the fast-evolving pharmaceutical sector.

Continue reading